RPL17 and hematologic disorder: The significant role that PD-1 and PD-L1 play in immunosuppression has been confirmed in recent years by the impressive effectiveness of PD-1 or PD-L1 blockade immunotherapy in treating many kinds of tumors, including hematologic malignancies (2, 3).